JP2000507544A
(ja)
|
1996-03-25 |
2000-06-20 |
イーライ・リリー・アンド・カンパニー |
痛みの治療方法
|
US6489341B1
(en)
|
1999-06-02 |
2002-12-03 |
Sepracor Inc. |
Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
|
ATE503845T1
(de)
*
|
2001-12-10 |
2011-04-15 |
Novartis Pharma Gmbh |
Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen
|
AU2004237951A1
(en)
*
|
2003-05-16 |
2004-11-25 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
|
GB0326148D0
(en)
|
2003-11-10 |
2003-12-17 |
Lilly Co Eli |
Morpholine derivatives
|
EP1696857A2
(en)
*
|
2003-12-04 |
2006-09-06 |
The Research Foundation Of the City university of New York |
Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal
|
EP1737473A4
(en)
*
|
2004-04-19 |
2009-08-26 |
Noven Therapeutics Llc |
COMBINATIONS OF LITHIUM AND USES THEREOF
|
BRPI0510942A
(pt)
*
|
2004-05-11 |
2007-07-17 |
Pfizer Prod Inc |
combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
|
MY147767A
(en)
*
|
2004-06-16 |
2013-01-31 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
TW200612905A
(en)
*
|
2004-06-16 |
2006-05-01 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
TW200616608A
(en)
*
|
2004-07-09 |
2006-06-01 |
Forest Laboratories |
Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
|
MX2007002309A
(es)
*
|
2004-08-24 |
2007-10-08 |
Johnson & Johnson |
Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos.
|
JP2008545650A
(ja)
*
|
2005-05-20 |
2008-12-18 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
スルファミド誘導体の製造方法
|
US20070212412A1
(en)
*
|
2005-09-08 |
2007-09-13 |
H. Lundbeck A/S |
Stable solid formulation of sertindole
|
US8937096B2
(en)
*
|
2005-12-19 |
2015-01-20 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
|
US8691867B2
(en)
*
|
2005-12-19 |
2014-04-08 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
|
US8492431B2
(en)
*
|
2005-12-19 |
2013-07-23 |
Janssen Pharmaceutica, N.V. |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
|
US8497298B2
(en)
*
|
2005-12-19 |
2013-07-30 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
|
US20070155827A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
|
US20070155823A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
|
US8716231B2
(en)
|
2005-12-19 |
2014-05-06 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
|
EP2026790A2
(en)
*
|
2006-05-19 |
2009-02-25 |
Janssen Pharmaceutica, N.V. |
Co-therapy for the treatment of epilepsy and related disorders
|
TW200821296A
(en)
*
|
2006-06-01 |
2008-05-16 |
Lundbeck & Co As H |
Use of sertindole for the preventive treatment of suicidal behaviour
|
EP2041304B1
(en)
|
2006-06-12 |
2011-09-07 |
Hadasit Medical Research Services & Development Limited |
Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
|
JP2010510314A
(ja)
|
2006-11-22 |
2010-04-02 |
シーサイド セラピューティクス,エルエルシー |
精神遅滞、ダウン症候群、脆弱x症候群および自閉症の治療方法
|
US20090247617A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Abdel-Magid Ahmed F |
Process for the preparation of benzo-fused heteroaryl sulfamates
|
EP2288345B1
(en)
|
2008-04-18 |
2015-06-10 |
University College Dublin National University Of Ireland, Dublin |
Psycho-pharmaceuticals
|
EA018567B1
(ru)
*
|
2008-06-23 |
2013-08-30 |
Янссен Фармацевтика Нв |
Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
|
EP2321011A1
(en)
*
|
2008-06-25 |
2011-05-18 |
Pfizer Inc. |
Diaryl compounds and uses thereof
|
US8815939B2
(en)
*
|
2008-07-22 |
2014-08-26 |
Janssen Pharmaceutica Nv |
Substituted sulfamide derivatives
|
US8252801B1
(en)
|
2009-06-03 |
2012-08-28 |
Abbott Laboratories |
Treatment of schizophrenia and related disorders
|
JP6440625B2
(ja)
|
2012-11-14 |
2018-12-19 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
精神分裂病を処置するための方法および組成物
|
WO2014144663A1
(en)
|
2013-03-15 |
2014-09-18 |
The Johns Hopkins University |
Methods and compositions for improving cognitive function
|
CA2904767C
(en)
|
2013-03-15 |
2022-06-21 |
Agenebio, Inc. |
Methods and compositions for improving cognitive function
|
US10925834B2
(en)
|
2015-05-22 |
2021-02-23 |
Agenebio, Inc. |
Extended release pharmaceutical compositions of levetiracetam
|